Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Myelodysplastic Syndromes 7Recurrence 6Hodgkin Disease 5Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Neuroblastoma 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Biphenotypic, Acute 3Leukemia 3Hematologic Neoplasms 3Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Burkitt Lymphoma 2Anemia, Refractory, with Excess of Blasts 2Transplant-Related Hematologic Malignancy 1Teratoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Pyloric Stenosis, Hypertrophic 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Osteosarcoma 1

Interventions

fludarabine phosphate 1Injections 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Filgrastim 1Etoposide 1Decitabine 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Myelomonocytic, Acute × Granulocyte Colony-Stimulating Factor × Clear all
NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
270 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡